Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.58 and traded as high as $0.63. Protagenic Therapeutics shares last traded at $0.55, with a volume of 110,680 shares.
Protagenic Therapeutics Stock Down 4.0 %
The business's 50 day simple moving average is $0.47 and its 200-day simple moving average is $0.58. The company has a market cap of $9.49 million, a price-to-earnings ratio of -2.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.93 and a current ratio of 14.93.
Get
Protagenic Therapeutics alerts:
Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) last issued its earnings results on Monday, November 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Protagenic Therapeutics
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent quarter. Institutional investors own 3.47% of the company's stock.
Protagenic Therapeutics Company Profile
(Get Rating)
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
Further Reading
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.58 and traded as high as $0.63. Protagenic Therapeutics shares last traded at $0.55, with a volume of 110,680 shares.
主角治療, 公司. (OTCMKTS: PTIX — 獲取評級) 上週四交易過程中越過其 200 天移動平均線以上.該股票的 200 天移動平均線為 0.58 美元，交易價格高達 0.63 美元。主角治療股票的最後交易價為 0.55 美元，成交量為 110,680 股。
Protagenic Therapeutics Stock Down 4.0 %
The business's 50 day simple moving average is $0.47 and its 200-day simple moving average is $0.58. The company has a market cap of $9.49 million, a price-to-earnings ratio of -2.51 and a beta of 0.06. The company has a debt-to-equity ratio of 0.04, a quick ratio of 14.93 and a current ratio of 14.93.
該業務的 50 天簡單移動平均線為 0.47 美元，其 200 天的簡單移動平均線為 0.58 美元。該公司的市值為 949 萬美元，價格與收益比為 -2.51，測試版為 0.06。該公司的債務與權益比率為 0.04，快速比率為 14.93，流動比率為 14.93。
Get
Protagenic Therapeutics
alerts:
Protagenic Therapeutics (OTCMKTS:PTIX – Get Rating) last issued its earnings results on Monday, November 14th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter.
主角治療（OTCMKTS：PTIX-獲取評級）上次發布了其收益業績，週一，11 月 14 日。該生物技術公司報告了本季度每股盈利（0.05 美元）。
Institutional Investors Weigh In On Protagenic Therapeutics
An institutional investor recently raised its position in Protagenic Therapeutics stock. Renaissance Technologies LLC boosted its position in shares of Protagenic Therapeutics, Inc. (OTCMKTS:PTIX – Get Rating) by 69.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 102,200 shares of the biotechnology company's stock after acquiring an additional 41,800 shares during the period. Renaissance Technologies LLC owned 0.59% of Protagenic Therapeutics worth $83,000 at the end of the most recent quarter. Institutional investors own 3.47% of the company's stock.
一家機構投資者最近提出了其在主角治療股票中的地位。文藝復興技術有限責任公司在最近的 13F 與證券交易委員會（SEC）提交的最新 13F 文件中，第一季度提高了其在主角治療公司（OTCMKTS：PTIX-獲得評級）的股份地位 69.2％。在此期間，該基金擁有該生物科技公司股票的 102,200 股股份。文藝復興技術有限責任公司擁有 0.59% 的主角治療，價值 83,000 美元在最近一個季度結束時。機構投資者擁有公司股票的 3.47%。
Protagenic Therapeutics Company Profile
Protagenic Therapeutics, Inc, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses.
主角治療公司，一家生物製藥公司，致力於治療與壓力相關的神經精神病和情緒障礙的治療藥物的發現和開發。它的鉛化合物是 PT00114，是一種 TENeuroin 羧終端相關肽的合成形式，是一種內源性腦信號肽，可抑制過度活躍的應激反應。
Further Reading
- Get a free copy of the StockNews.com research report on Protagenic Therapeutics (PTIX)
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving '23 Growth
- Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
- Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
- Microsoft Layoffs Signal Layoffs for Other Tech Companies?
- 獲取有關主角治療研究報告的免費副本
- 埃克森美孚股票：在買入點的醒目距離內
- 高股息收益的必和必拓認為中國推動 23 年增長
- Airbnb 是否正在設置上漲 38％，正如分析師的預測？
- 特斯拉車輛的降價是否意味著 TSLA 股票相同？
- 微軟裁員信號裁員為其他科技公司？
Receive News & Ratings for Protagenic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagenic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收主角治療的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收有關主角治療和相關公司的最新新聞和分析師評級的簡要每日摘要。
